Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air Inc. is experiencing a positive trajectory, highlighted by a 105% increase in fiscal 3Q26 revenue to $2.2 million, indicating strong demand for its LungFit PH device and successful penetration into the U.S. market, exemplified by its first sale to a VA Medical Center. The company's expanding international distribution network, now in 40 countries, further enhances its growth potential and market presence. Additionally, encouraging preliminary data from the intratumoral ultra-high concentration Nitric Oxide (UNO) program suggests a promising therapeutic profile, which may enhance Beyond Air's credibility and prospects as it continues to innovate in the respiratory and oncology sectors.

Bears say

Beyond Air Inc is shifting its focus for its Nitric Oxide (NO) Generator and Delivery System, now positioning it as an immunotherapy enhancer instead of merely a standalone ablation tool, which may indicate challenges in establishing a distinct market presence for the product. The change in strategy reflects possible underlying concerns regarding the effectiveness and market acceptance of their primary offering, particularly in competitive therapeutic areas like immunotherapy for respiratory diseases. These factors, combined with the company's commercialization stage and potential revenue uncertainties, contribute to a negative outlook on Beyond Air's stock.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.